Agomab receives U.S. patent for AGMB-447

Agomab (AGMB) announced that the United States Patent and Trademark Office, or USPTO, has granted U.S. Patent No. 12,577,230, covering the composition of matter of AGMB-447, to Agomab. AGMB-447 is the company’s investigational inhaled lung-restricted small molecule inhibitor of ALK5, currently in a Phase 1b study for the treatment of Idiopathic Pulmonary Fibrosis. This patent provides intellectual property protection for AGMB-447 in the U.S. through at least 2041, excluding any potential patent term extensions.